American Association for Cancer Research
00085472can121013-sup-f4_639k.pdf (639.08 kB)

Supplementary Figures 1-6 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Download (639.08 kB)
journal contribution
posted on 2023-03-30, 21:29 authored by Lixing Zhang, Hefen Sun, Fangyu Zhao, Ping Lu, Chao Ge, Hong Li, Helei Hou, Mingxia Yan, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Xiaowu Huang, Jia Fan, Ming Yao, Jinjun Li

PDF file - 639K, Supplementary Figure 1. CD133 is CSCs surface marker in PLC/PRF/5 cell line. Supplementary Figure 2. BMP4 showed pro-differentiation effect on HCC cell lines. Supplementary Figure 3. Tumorigenicity of CD133+/- HCC cells co-injected with BMP4 or vehicle embedding beads. Supplementary Figure 4. Canonical BMP4 signaling pathway switches on after exogenous BMP4 treatment. Supplementary Figure 5. BMP4 and SMAD6 expression in HCC cell lines. Supplementary Figure 6. Differentiated CSCs displayed enhanced Erk1/2 phosphorylation.



CD133+ cancer stem cells (CSC) contribute to hepatocellular carcinoma (HCC) progression and resistance to therapy. Bone morphogenetic protein BMP4 plays an important role in hepatogenesis and hepatic stem cell differentiation, but little is known about its function in hepatic CSCs. In this study, we showed that high-dose exogenous BMP4 promotes CD133+ HCC CSC differentiation and inhibits the self-renewal, chemotherapeutic resistance, and tumorigenic capacity of these cells. Interestingly, we found that low-dose exogenous BMP4 upregulated CD133 protein expression in vitro, and endogenous BMP4 was preferentially expressed in CD133+ HCC CSCs, suggesting that low doses of BMP4 may facilitate CSC maintenance. A reduction in endogenous BMP4 levels decreased CD133 protein expression in vitro. In HCC tissues, expression of the BMP4 signaling target gene SMAD6 was positively correlated with CD133 expression. Activation of the Erk1/2 signaling pathway led to BMP4-mediated reduction in CD133 expression, which was reversed by treatment with MEK inhibitors. Taken together, our findings indicated that BMP4 might be a potent therapeutic agent in HCC that targets CSCs. Cancer Res; 72(16); 4276–85. ©2012 AACR.